Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
British Journal of Cancer|September 30, 2021
Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemicAlexandra Bizot, Maryam Karimi, Elie Rassy, et al.
Breast (Edinburgh, Scotland)|February 9, 2021
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME programLuc Cabel, Matthieu Carton, Barbara Pistilli, et al.
Breast Cancer Research and Treatment|October 26, 2018
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimensLuc Cabel, Matthieu Carton, Bianca Cheaib, et al.
BMC Medicine|March 7, 2023
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world databaseCoralie Courtinard, Sophie Gourgou, William Jacot, et al.
The Oncologist|August 17, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME ProgramFanny Le Du, Matthieu Carton, Thomas Bachelot, et al.
International Journal of Cancer|September 26, 2022
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world databaseAudrey Mailliez, Veronique D'Hondt, Amelie Lusque, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerVeronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 1, 2020
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer ScreeningRita Tanos, Guillaume Tosato, Amaelle Otandault, et al.
Breast (Edinburgh, Scotland)|March 17, 2022
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohortFabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
British Journal of Cancer|September 30, 2021
Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemicAlexandra Bizot, Maryam Karimi, Elie Rassy, et al.
Breast (Edinburgh, Scotland)|February 9, 2021
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME programLuc Cabel, Matthieu Carton, Barbara Pistilli, et al.
Breast Cancer Research and Treatment|October 26, 2018
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimensLuc Cabel, Matthieu Carton, Bianca Cheaib, et al.
BMC Medicine|March 7, 2023
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world databaseCoralie Courtinard, Sophie Gourgou, William Jacot, et al.
The Oncologist|August 17, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME ProgramFanny Le Du, Matthieu Carton, Thomas Bachelot, et al.
International Journal of Cancer|September 26, 2022
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world databaseAudrey Mailliez, Veronique D'Hondt, Amelie Lusque, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerVeronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 1, 2020
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer ScreeningRita Tanos, Guillaume Tosato, Amaelle Otandault, et al.
Breast (Edinburgh, Scotland)|March 17, 2022
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohortFabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, et al.
Pageof 20